Segall Bryant & Hamill LLC Sells 3,047 Shares of Stryker Corporation (NYSE:SYK)

Segall Bryant & Hamill LLC reduced its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 5.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,775 shares of the medical technology company's stock after selling 3,047 shares during the period. Segall Bryant & Hamill LLC's holdings in Stryker were worth $21,134,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Brighton Jones LLC lifted its stake in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in Stryker by 46.2% during the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock valued at $596,000 after purchasing an additional 523 shares during the last quarter. GWN Securities Inc. acquired a new position in shares of Stryker in the fourth quarter valued at $231,000. Creative Financial Designs Inc. ADV lifted its stake in shares of Stryker by 25.6% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 398 shares of the medical technology company's stock worth $143,000 after buying an additional 81 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in Stryker by 1.9% in the 4th quarter. Parallel Advisors LLC now owns 15,712 shares of the medical technology company's stock valued at $5,657,000 after buying an additional 300 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director directly owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SYK. Citigroup restated a "buy" rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research note on Monday, May 5th. Roth Mkm boosted their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Evercore ISI boosted their price target on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $428.55.

Stryker Trading Down 0.4%

Shares of Stryker stock traded down $1.64 during trading on Thursday, hitting $389.23. The company's stock had a trading volume of 648,437 shares, compared to its average volume of 1,350,937. The stock has a 50-day moving average price of $385.38 and a two-hundred day moving average price of $377.55. Stryker Corporation has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market cap of $148.57 billion, a price-to-earnings ratio of 52.57, a price-to-earnings-growth ratio of 2.95 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the previous year, the firm earned $2.50 earnings per share. The firm's quarterly revenue was up 11.9% on a year-over-year basis. Equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.